Cargando…
When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
Autores principales: | Iguchi, Moritake, Wada, Hiromichi, Martínez, Felipe, Hasegawa, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345959/ https://www.ncbi.nlm.nih.gov/pubmed/37456773 http://dx.doi.org/10.15420/ecr.2022.62 |
Ejemplares similares
-
SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020) -
Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know
por: Martínez, Felipe
Publicado: (2021) -
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020) -
Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Tamargo, Juan
Publicado: (2019) -
Adaptive servoventilation versus oxygen therapy for sleep disordered breathing in patients with heart failure: a randomised trial
por: Murase, Kimihiko, et al.
Publicado: (2016)